Publikationen, an denen er mitarbeitet Rocío Gallego Durán (19)

2024

  1. Fibroblast growth factor 21 is a hepatokine involved in MASLD progression

    United European Gastroenterology Journal, Vol. 12, Núm. 8, pp. 1056-1068

  2. Proceedings of the 5th Meeting of Translational Hepatology, organized by the Spanish Association for the Study of the Liver (AEEH)

    Gastroenterologia y Hepatologia

  3. Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver disease

    Gut, Vol. 73, Núm. 5, pp. 825-834

  4. The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis

    Journal of Gastroenterology, Vol. 59, Núm. 7, pp. 586-597

2023

  1. Role of EpCAM+ CD133+ extracellular vesicles in steatosis to steatohepatitis transition in NAFLD

    Liver International, Vol. 43, Núm. 9, pp. 1909-1919

2022

  1. Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: Time for reappraisal of BMI-driven approach?

    Gut, Vol. 71, Núm. 2, pp. 382-390

  2. Liver injury in non-alcoholic fatty liver disease is associated with urea cycle enzyme dysregulation

    Scientific Reports, Vol. 12, Núm. 1

2021

  1. Copy number variation and expression of exportin-4 associates with severity of fibrosis in metabolic associated fatty liver disease

    EBioMedicine, Vol. 70

  2. Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects

    Liver International, Vol. 41, Núm. 9, pp. 2076-2086

  3. Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease

    Journal of Hepatology, Vol. 75, Núm. 4, pp. 786-794

  4. Mistranslation Drives Alterations in Protein Levels and the Effects of a Synonymous Variant at the Fibroblast Growth Factor 21 Locus

    Advanced Science, Vol. 8, Núm. 11

2020

  1. Development and Validation of Hepamet Fibrosis Scoring System–A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis

    Clinical Gastroenterology and Hepatology, Vol. 18, Núm. 1, pp. 216-225.e5

  2. Erratum to: “Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH (J Hepatol 2020; 73: 17–25) (Journal of Hepatology (2020) 73(1) (17–25), (S0168827820301276), (10.1016/j.jhep.2020.02.028))

    Journal of Hepatology

  3. Genetic variation in the TLL1 gene is not associated with fibrosis in patients with metabolic associated fatty liver disease

    PLoS ONE, Vol. 15, Núm. 12 December

  4. Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH

    Journal of Hepatology, Vol. 73, Núm. 1, pp. 17-25

2019

  1. A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3′UTR

    Journal of Hepatology, Vol. 70, Núm. 3, pp. 494-500

2018

  1. Erratum to «Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline» [Gastroenterol Hepatol. 2018;41(5):328-349] (S0210570518300037) (10.1016/j.gastrohep.2017.12.003))

    Gastroenterologia y Hepatologia

  2. The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity

    Alimentary Pharmacology and Therapeutics, Vol. 48, Núm. 11-12, pp. 1260-1270

2017

  1. Co-20. Validación de los índices fib 4 y nfs para discriminar fibrosis hepática en pacientes con eghna en práctica clínica habitual.

    Revista andaluza de patología digestiva, Vol. 40, Núm. 5, pp. 282-283